Figures & data
Table I. The clinical characteristics of the patients in the three groups.
Figure 1. Immunohistochemical staining of securin (a) and Ki-67 (b) in rectal cancer. Staining pattern of Ki-67 was almost exclusively nuclear, while securin had a combination of nuclear and cytoplasmic staining with a clear prominence of nuclear one.
![Figure 1. Immunohistochemical staining of securin (a) and Ki-67 (b) in rectal cancer. Staining pattern of Ki-67 was almost exclusively nuclear, while securin had a combination of nuclear and cytoplasmic staining with a clear prominence of nuclear one.](/cms/asset/f9277389-eddc-4f1b-b23c-2e26117665d3/ionc_a_584327_f0001_b.jpg)
Table II. The expression of securin and Ki-67 in the operative specimens related to key clinicopathological variables.
Table III. The pairwise-comparison of biopsy and operative specimens according to securin and Ki-67 expression.